Before taking the corner office at ViCentra, Arnold held leadership roles at Medtronic, Procept BioRobotics, Boston Scientific and Sorin Group. Most recently, he served as VP of global marketing at ...

The FDA has approved Medtronic's Brainsense Adaptive deep brain stimulation for patients with Parkinson's disease. The technology is designed to adjust therapy in real time based on a patient's ...

Seventeen years before Medtronic’s recent FDA approval for the world’s first adaptive deep brain stimulation (DBS) system for Parkinson’s disease, Scott Stanslaski was just starting his work on the ...

Shortly after obtaining a greenlight in Europe and after more than 10 years in development, Medtronic has now received the FDA’s approval for its adaptive, closed-loop neurostimulation approach ...

Medtronic’s Percept PC neurostimulator with BrainSense technology [Image courtesy of Medtronic] Medtronic (NYSE: MDT) + announced today that the FDA approved its BrainSense adaptive deep brain ...

AI-enhanced insulin management: AI-driven tools like Advisor Pro and Medtronic Guardian Connect System can remotely adjust insulin doses and predict hypoglycemic events with up to 98.5% accuracy, ...

The spinal system adds to Medtronic’s expanding lumbar fixation offerings. Credit: sockagphoto / Shutterstock. Global healthcare technology developer Medtronic has launched the CD Horizon ModuLeX ...

Last week, Guardian Media Group (GMG), which owns Guardian Australia and its UK and US counterparts, announced a strategic partnership with the American artificial intelligence organisation OpenAI.

A clinician uses Medtronic's pulsed field ablation system for treating atrial fibrillation last month. On Tuesday, Medtronic reported adjusted quarterly net profit of $1.8 billion on $8.3 billion ...

VCG / Contributor / Getty Images Medtronic shares slumped Tuesday after the medical device maker missed sales forecasts. The revenue miss came as sales of its stapling and blood oxygen management ...

Medtronic posted a strong profit for Q3 of fiscal year 2025, though shares were down as its cardiac ablation product success was offset by weaker sales from its medical-surgical business.

Medtronic missed Wall Street's fiscal 2025 Q3 revenue estimate but beat earnings expectations. The company's revenue miss appears to be primarily related to a temporary change in distributor ...